The epidermal growth factor receptor (EGFR) mutant of EGFRvIII is highly expressed in glioma cells, and the EGFRvIII-specific dendritic cell (DC)-induced tumor antigen-specific CD8+ cytotoxic T lymphocytes (CTLs) may hold promise in cancer immunotherapy. This evidence concerns the gene EGFR and glioma.